



Robyn Boerstling

Vice President

Infrastructure, Innovation and Human Resources Policy

March 22, 2017

Michael C. Burgess
Chairman, Subcommittee on Health
Energy and Commerce Committee
United States House of Representatives
Washington, DC 20515

Gene Green
Ranking Member, Subcommittee on Health
Energy and Commerce Committee
United States House of Representatives
Washington, DC 20515

Dear Chairman Burgess and Ranking Member Green:

On behalf of the National Association of Manufacturers (NAM), the largest manufacturing association in the United States representing 14,000 manufacturers in every industrial sector and in all 50 states, I am writing to express strong support for a swift and timely reauthorization of the Prescription Drug User Fee Act of 2017, also known as PDUFA VI.

Manufacturers appreciate the Committee's attention to this issue and today's hearing to discuss advancing legislation that will support America's innovation leadership in the field of life sciences. The Food and Drug Administration's PDUFA is the ultimate public-private partnership that supports patients who need life-saving medical treatments while advancing science, research and technological innovation. There are approximately 7,000 medicines currently in development. Consistency, certainty and predictability are required for safe, effective and timely drug reviews.

Manufacturers in the United States drive these breakthroughs and serve as a global leader in a variety of fields, including the pharmaceutical industry. The recently enacted and NAM-supported 21st Century Cures Act will further modernize our approach to the discovery, development, and delivery of medical innovations. PDUFA VI is a necessary and complementary program to accelerate new medical breakthroughs. Any delay to the PDUFA reauthorization risks future gains in medical discovery and harm to our global standing.

The United States leads the world in the introduction of new medicines. Manufacturers support research pipelines that will lead to further advancement in the development of treatments and products as well as the creation of more jobs that support innovation and scientific advancement. Today's hearing is an important step and manufacturers urge the Energy and Commerce Committee to support the momentum initiated by your leadership.

Sincerely,

A handwritten signature in blue ink that reads 'Robyn M. Boerstling'.

Robyn M. Boerstling

Leading Innovation. Creating Opportunity. Pursuing Progress.